Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and -resistant Staphylococcus aureus by Schaad, Heinz J. et al.
Journal of Antimicrobial Chemotherapy (1994) 33, 1191-1200
Comparative efficacies of imipenem, oxacillin and vancomycin for
therapy of chronic foreign body infection due to methicillin-susceptible
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The efficacies of imipenem when directed against methicillin-susceptible (MSSA) and
methicillin-resistant (MRSA) strains of Staphylococcus aureus were compared with
those of oxacillin and vancomycin in a subcutaneous rat model, using chronically
infected tissue cages. At three weeks after inoculation, stable chronic infections were
established with average bacterial counts exceeding 106cfu/mL tissue cage fluid for
both strains. Intraperitoneal administration (twice a day for 7 days) of imipenem
(80 mg/kg) or oxacillin (200 mg/kg) produced peak levels of 23 or 45 mg/L and
trough levels of < 0-1 and 5-7 mg/L, respectively. The therapeutic regimens of either
imipenem (P < 0-001) or oxacillin (P < 0-02) administered for 7 days led to signifi-
cant reductions in bacterial counts in the tissue cage fluids of animals chronically
infected with MSSA. In contrast, imipenem was not effective against chronic MRSA
tissue cage infections, despite the relatively low MIC of the infecting strain and the
use of high dose (120 mg/kg) therapy. In-vitro susceptibility testings of MRSA
performed before and after imipenem therapy demonstrated the emergence of a
highly resistant subpopulation.
Introduction
Foreign body infections are a major source of patient morbidity and implant failure.
They can affect not only orthopaedic prostheses but also intravascular catheters and
artificial heart valves (Bisno, 1989; Brause, 1989; Karchmer & Bisno, 1989). Several
clinical and experimental studies have documented the frequent failure of antimicrobial
agents to eradicate staphylococcal infections associated with foreign implants or
devices (Bisno, 1989; Brause, 1989; Karchmer & Bisno, 1989). The reasons for this lack
of effectiveness are still poorly understood and may involve alterations in the surfaces
of the bacteria colonizing implants (Gristina & Costerton, 1985; Chuard et al., 19916),
impairment in the host defense mechanisms (Zimmerli, Lew & Waldvogel, 1984;
Vaudaux, Lew & Waldvogel, 1989), or both.
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To screen for new agents or to test new regimens for effective therapy of chronic
foreign body infections, we recently developed a rat model of subcutaneous foreign
body infection. This model has provided useful information in showing the advantage
of combination therapy over monotherapy, over periods of 1 (Lucet et al., 1990) to 3
weeks (Chuard et al., 1991a).
Imipenem is a highly active, broad-spectrum antibiotic with good tissue penetration
(Drusano, 1986; Wise et al., 1986) and a low frequency of side effects (Calandra et al.,
1986). Imipenem is extremely resistant to the staphylococcal /Mactamase and shows
high activity against methicillin-susceptible strains of Staphylococcus aureus (Witte,
Sapico & Canawati, 1982). The first aim of this study was to evaluate the efficacy of
imipenem, as compared to oxacillin, in the experimental model of chronic tissue cage
infection by a methicillin-susceptible strain of S. aureus. The second objective was to
evaluate the response of a heterogeneous methicillin-resistant strain of S. aureus to a
high dose imipenem therapy and compare this to the response to vancomycin in the
tissue cage model of chronic infection, because, although the use of imipenem against
methicillin-resistant strains is not recommended (Chambers, 1988; Brumfitt &
Hamilton-Miller, 1989), determination of its efficacy in vivo in the clinical situation
(Fan et al., 1986) and in animal models of infections by methicillin-resistant strains of
staphylococci has yielded conflicting data (Berry, Johnston & Archer, 1986;
Chandrasekar et al., 1988).
Materials and methods
Antimicrobial agents and media
For in-vitro studies, laboratory standards of the antimicrobials used with known
potency were supplied as follows: imipenem by Merck Sharp & Dohme-Chibret, USA,
oxacillin by Sigma, USA, and vancomycin by Eli Lilly, Germany. For animal studies, a
1 : 1 ratio of imipenem and cilastatin, (Tienam, Merck Sharp & Dohme-Chibret,
Switzerland) and vancomycin (Eli Lilly, Germany) were used and were dissolved in
solvents as recommended by their manufacturers. Oxacillin (Sigma) was freshly
dissolved in distilled water at a concentration of 20 mg/mL.
A single batch of Mueller-Hinton broth (Difco, USA), with low contents of Ca2+
(16mg/L) and Mg2+ (7 mg/L), was used. To estimate antibacterial activity in vitro,
Mueller-Hinton broth was supplemented (MHB-S) with Ca2+ 50 mg/L and Mg2+
25 mg/L. When indicated, MHB-S was supplemented with 2% NaCl (w/v).
Bacteria
The methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains of
S. aureus used for the animal studies were MSSA strain 120 (Chuard et al., 1991ft) and
MRSA multiresistant strain MRGR3 (Lucet et al., 1990). Both strains were isolated
from patients with catheter-related sepsis and were selected for their virulence proper-
ties in the rat model of chronic tissue cage infections. Strain MRGR3 is resistant to
methicillin and shows additional resistances to benzylpenicillin, gentamicin, chlor-
amphenicol, erythromycin, tetracycline and polymyxin B.
One hundred and seven strains of S. aureus isolated at the University Hospital of
Geneva were also tested for in-vitro susceptibility to imipenem. They comprised 57
MSSA and 50 MRSA strains.
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In-vitro studies
The MICs of imipenem for the 107 clinical isolates of S. aureus were determined by a
previously described agar dilution method (Rohner et al., 1992). The medium used was
Mueller-Hinton agar (Oxoid, Basingstoke, UK) and plates were inoculated with 104 cfu
as previously described (Rohner et al., 1992). The MIC was determined as the lowest
concentration of imipenem which completely inhibited growth, disregarding a single
colony or a faint haze of growth.
The MICs and MBCs of imipenem and oxacillin for MSSA strain 120 and of
imipenem and vancomycin for MRSA strain MRGR3 were determined by a macrodi-
lution broth method using MH-S medium as indicated above and a standard inoculum
of 106 cfu/mL. MIC tests were read after 24 h or, when indicated, after 48 h incubation
at 37°C. To test for possible carry-over effects of each antibiotic during MBC
determinations, 01 mL portions were taken from all tubes with no visible growth.
These were subcultured, either undiluted or serially diluted 10-fold in saline, on
Mueller-Hinton agar (Difco) for 24 h or, when indicated, for 48 h at 35°C. The MBC
was denned as the lowest concentration of antibiotic that killed 99-9% of the original
inoculum (National Committee for Clinical Laboratory Standards, 1987). For MRSA
strain MRGR3, MICs and MBCs were also tested in MH-S broth supplemented with
2%NaCl.
Time kill studies were performed with antibiotic concentrations corresponding to
those found in tissue cage fluid (TCF), namely oxacillin 8 mg/L with MSSA and
imipenem 8 mg/L or vancomycin 8 mg/L with MRSA. These levels are equivalent to
8-16 times the MICs for the respective strains. A much lower concentration (0-2 mg/L)
of imipenem, equivalent to ten-times its MIC for MSSA, was used for time kill studies
with this strain to avoid significant carryover effects. Glass tubes containing 10 mL of
Mueller-Hinton broth were inoculated to a cell density of 106cfu/mL from a culture
that had been grown exponentially for 3 h, in a shaking waterbath at 37°C. The number
of viable organisms was determined by spreading 005 mL of ten-fold serially diluted
portions of culture on Mueller-Hinton agar after 0, 2, 4, 6 and 24 h incubation.
Bacteria were spread wth a spiral plater (Spiral System, Cincinnati, USA) and colonies
counted with a laser colony counter (Spiral System) after 24 h incubation at 37°C. The
detection limit was 2 log,0 cfu/mL with all antibiotics tested. Comparison of viable
counts obtained with the ten-fold serially diluted portions following a procedure
previously described in detail (Lucet et al., 1990; Chuard et al., 1991a, 1992) indicated
the absence of significant carryover of antibiotics under these experimental conditions.
Treatment of chronic foreign body infections
Animal experiments received the approval of the Ethical Committee of the University
Hospital and of the State Veterinarian Office of Geneva. Four polytetrafluorethylene
(Teflon) tissue cages were implanted subcutaneously in each Wistar rat as described
previously (Lucet et al., 1990). At three weeks after implantation, a 50//L-portion of the
fluid that had accumulated (approximate volume: 1 mL) in each cage (designated tissue
cage fluid) was aspirated and checked for sterility. Then the cages were inoculated with
01 mL of saline containing 0-2 x 106 to 2 x 106cfu of MSSA or MRSA. Three weeks
later, all tissue cages containing more than 1 x 105cfu/mL TCF were included in the
therapeutic protocol. Rats infected with MSSA were randomized to receive (by
intraperitoneal route twice a day for 7 days) either imipenem (80 mg/kg) plus cilastatin,
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or oxacillin (200 mg/kg), or were left untreated. Rats infected with strain MRGR3
received (twice a day for 7 days) either imipenem (120 mg/kg) plus cilastatin, or
vancomycin (50 mg/kg), or were left untreated. Twelve hours after the last injection of
antibiotic, viable counts in 10-fold serially diluted TCF were obtained on
Mueller-Hinton agar. Possible clumps of bacteria were disrupted by sonication of TCF
for 1 min at 60 W (Branson 2200, Branson Ultrasonics, Danbury, USA) before plating.
Quantitative bacterial counts were determined, with a detection limit of lOOcfu/mL,
and expressed as log,0 cfu/mL. For each cage, the difference between cfu counts from
day 1 and day 8 were determined and expressed as delta log,0 cfu/mL.
For each group and treatment regimen, results were expressed as means+ S.E.M.
Comparisons of bacterial counts in the different groups were done using the non-
parametric Kruskall-Wallis test and the Dunn procedure for comparison of specific
groups (Rosner, 1990). Data were considered significant when P was < 005, using
two-tailed significance levels.
Pharmacokinetics of antimicrobial agents
The pharmacokinetic properties of vancomycin in the TCF of rats were already known
from previous studies (Lucet et al., 1990). Concentrations of imipenem and oxacillin in
serum and TCF of non-infected animals were measured by bioassay at various time
intervals (30 min, 1, 2, 4, 6, 8 and 12 h) after administration of the antibiotics. The test
organism was a spore suspension of Bacillus subtilis. To prevent degradation of
imipenem samples, serum or TCF were mixed with an equal volume of 1 M morpho-
lineoethane sulfonate buffer (Fluka, Sargans, Switzerland) at pH6 and ethylene glycol
(Fluka). In rats, the pharmacokinetics of imipenem and oxacillin were determined at
both day 1 and day 7 of therapy.
Results
Treatment of chronic MSSA tissue cage infections
The MIC/MBC of oxacillin and imipenem for MSSA strain 120 were 0-5/1 mg/L and
0-02/0-02 mg/L, respectively. The MIC of imipenem for strain 120 fell within the range
of MICs of a group of 57 clinical isolates of MSSA, all of which were inhibited by
imipenem 006 mg/L.
In time kill studies, incubation of MSSA with a low concentration (0-2 mg/L) of
imipenem, selected to avoid antibiotic carry over, resulted in a rapid in-vitro elimina-
tion of the bacteria by at least 3 log,0cfu/mL within 4 h. A similar decrease in viable
counts was observed when the MSSA strain was exposed to oxacillin 8 mg/L (not
shown).
Addition of 50% TCF to MHB-S medium, when estimating antibacterial activity
in vitro, did not significantly modify the MIC, the MBC or the bactericidal activity of
each antibiotic compared with unsupplemented MHB-S medium (not shown).
During therapy with imipenem (80 mg/kg) plus cilastatin twice a day, average
concentrations of imipenem peaked at 23 mg/L in rat TCF 2 h after administration.
The rate of elimination of imipenem from TCF was rapid, with residual levels of 0-29
and < 01 mg/L after 8 and 12 h, respectively. The pharmacokinetic properties of
imipenem in TCF, which were similar at day 1 (not shown) and day 7 (Figure l(a)
indicated an average concentration of antibiotic exceeding the MIC for MSSA for a
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Figure 1. Concentration of imipenem in serum ( # ) and tissue cage fluid (O) of rats at day 7 after twice a
day intraperitoneal administration of imipenem plus cilastatin. (a) Imipenem 80 mg/kg twice a day; (b)
imipenem 120 mg/kg twice a day.
10h-period during each 12-h cycle of therapy. In comparison, administration of
oxacillin (200 mg/kg twice a day) resulted in average TCF levels that continually
exceeded the MIC for MSSA (peak: 45 mg/L; trough: 57 mg/L).
Of 71 tissue cages inoculated with strain 120, 11 with bacterial counts less than
105cfu/mL TCF before the onset of therapy were excluded from the study. At day 1,
before antibiotic treatment, similar average bacterial counts were found in the fluids of
the residual 60 tissue cages. The animals were subdivided into three groups with the
following TCF counts: 6-85 + 0-27 for the 19 cages of control rats, 6-58 + 0-18 for the 23
cages of rats receiving imipenem, and 6-82 + 0-17 logl0cfu/mL for the 18 cages of rats
receiving oxacillin. At the end of the 7-day treatment period, cfu counts in TCFs of
untreated animals increased slightly and non-significantly by 0-48 + 0-24 log|0cfu/mL
(n = 19). Both imipenem and oxacillin therapy led to significant decreases in viable
counts of TCFs by 1-76 + 0-26 (n = 23, P < 0001) and 0-92 + 0-21 (« = 18, P < 002)
log10 cfu/mL, respectively (Figure 2(a)).
Treatment of chronic MRS A tissue cage infection
The MIC/MBC values of oxacillin and vancomycin for MRSA strain MRGR3 were
16/64 and 1/2 mg/L, respectively. In repeated experiments (« = 6), the MICs of
imipenem for the MRSA strain MRGR3 ranged from 0125-1 mg/L and the MBCs
from 16-32 mg/L. This MIC of imipenem for strain MRGR3 was at the lower end of
the range of those obtained (0-06 to > 64 mg/L) for a group of 50 clinical isolates of
MRSA using agar dilution testing.
In time kill studies, MRSA strain MRGR3 exposed to imipenem 8 mg/L showed
incomplete elimination of 1-2-5 log10cfu/mL during the initial 6 h, followed by partial
regrowth thereafter. In similar conditions, vancomycin eliminated the test strain by
> 3 log,0 cfu/mL at 24 h (data not shown).
To achieve TCF levels of imipenem active against MRSA strain MRGR3, a high
dose regimen of 120 mg/kg was administered to infected animals twice a day for 7 days.
This resulted in peak and trough levels of imipenem in TCF averaging 26 and 0-5 mg/L,
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Figure 1. Concentration of imipenem in serum (#) and tissue cage fluid (O) of rats at day 7 after twice a
day intraperitoneal administration of imipenem plus cilastatin. (a) Imipenem 80 mg/kg twice a day; (b)
imipenem 120 mg/kg twice a day.
10h-period during each 12-h cycle of therapy. In comparison, administration of
oxacillin (200 mg/kg twice a day) resulted in average TCF levels that continually
exceeded the MIC for MSSA (peak: 45 mg/L; trough: 57 mg/L).
Of 71 tissue cages inoculated with strain 120, 11 with bacterial counts less than
105cfu/mL TCF before the onset of therapy were excluded from the study. At day 1,
before antibiotic treatment, similar average bacterial counts were found in the fluids of
the residual 60 tissue cages. The animals were subdivided into three groups with the
following TCF counts: 6-85 + 0-27 for the 19 cages of control rats, 6-58 ±0-18 for the 23
cages of rats receiving imipenem, and 6-82 ±017 logl0cfu/mL for the 18 cages of rats
receiving oxacillin. At the end of the 7-day treatment period, cfu counts in TCFs of
untreated animals increased slightly and non-significantly by 0-48 + 0-24 log|0cfu/mL
{n = 19). Both imipenem and oxacillin therapy led to significant decreases in viable
counts of TCFs by 1-76±0-26 (n = 23, P < 0001) and 0-92 + 0-21 (n = 18, P < 002)
log10 cfu/mL, respectively (Figure 2(a)).
Treatment of chronic MRS A tissue cage infection
The MIC/MBC values of oxacillin and vancomycin for MRSA strain MRGR3 were
16/64 and 1/2 mg/L, respectively. In repeated experiments (« = 6), the MICs of
imipenem for the MRSA strain MRGR3 ranged from 0125-1 mg/L and the MBCs
from 16-32 mg/L. This MIC of imipenem for strain MRGR3 was at the lower end of
the range of those obtained (0-06 to > 64 mg/L) for a group of 50 clinical isolates of
MRSA using agar dilution testing.
In time kill studies, MRSA strain MRGR3 exposed to imipenem 8 mg/L showed
incomplete elimination of 1-2-5 log10cfu/mL during the initial 6 h, followed by partial
regrowth thereafter. In similar conditions, vancomycin eliminated the test strain by
> 3 log|0 cfu/mL at 24 h (data not shown).
To achieve TCF levels of imipenem active against MRSA strain MRGR3, a high
dose regimen of 120 mg/kg was administered to infected animals twice a day for 7 days.
This resulted in peak and trough levels of imipenem in TCF averaging 26 and 0-5 mg/L,
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Figure 2. Reduction in bacterial counts of S. aureus in chronic tissue cage infection during a 7 day
antimicrobial therapy, (a) Methicillin-susceptible strain 120; (b) methicillin-resistant strain MRGR3.
respectively, almost continuously exceeding the MIC for MRSA during therapy
(Figure l(b)). In comparison, animals receiving vancomycin (50mg/kg) twice a day
had average antibiotic levels that constantly exceeded the MIC for MRSA, with peak
and trough levels of 12 and 2 mg/L at 4 and 12 h, respectively.
For the comparative therapeutic trial, 78 cages were infected with MRSA strain
MRGR3. Subsequently, 16 with inadequate bacterial counts were excluded from the
study. At day 1, before therapy was started, average bacterial counts were similar in
TCFs of untreated animals (6-26 ±0-22; « = 1 7 ) and those receiving imipenem
(6-33 ±0-20; n = 23) or vancomycin (6-11 ±0-21; n = 22). At the end of the seven-day
treatment period, TCFs from vancomycin-treated animals showed a significant (P <
0-002) decrease in their viable counts of 111 ±0-26 logl0cfu/mL (Figure 2(b)). In
contrast, high dose therapy with imipenem plus cilastatin did not lead to a reduction in
TCF bacterial counts, but rather to a slight increase of 0-30 ± 0 1 6 logl0cfu/mL, similar
to that recorded in TCFs of untreated animals (0-31 ±0-33 logl0cfu/mL, Figure 2(b)).
To investigate further the lack of activity shown by imipenem for MRSA in tissue
cage infections, additional in-vitro and in-vivo studies were performed. Various altera-
tions in culture media and incubation conditions, known to influence expression of
methicillin resistance, were made to determine the effects on the MIC of imipenem.
These changes included addition of sodium chloride to the medium, a lower tempera-
ture of incubation, and an incubation time extended to 48 h. Whereas adding 2% NaCl
to the medium or incubation at 30°C did not alter the MIC of imipenem for strain
MRGR3 when the plates were read at 24 h (range from 0-125—1 mg/L in repeated
experiments (n = 6)), the MICs of imipenem were increased to 16-32 mg/L when plates
were read at 48 h. Such a large ( > 32-fold) increase in MIC obtained simply by
extending the incubation time from 24 to 48 h could be accounted for by the presence
of a slowly growing subpopulation of bacteria highly resistant to imipenem.
Microcolonies were faintly visible at 24 h, but could not properly be enumerated
before at least 48 h of incubation. A similar situation was observed at the end of time
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kill studies performed with imipenem 8 mg/L. After 24 h incubation, tubes contained a
majority of faintly visible microcolonies which, following further growth and suspen-
sion in MHB-S showed high resistance to imipenem (MIC: 32 mg/L) in the macrodilu-
tion broth method.
Two experiments were performed in vivo to study the selection or induction of
imipenem resistance during imipenem therapy. In the first experiment, six animals were
treated twice a day for 4 days with imipenem 80 mg/kg and the number of imipenem-
resistant cells, namely those able to grow on agar supplemented with imipenem 8 mg/L,
were scored before and after therapy. In 16 TCF samples, containing at least
105cfu/mL at the onset of therapy, the median frequency of highly resistant organisms
was 2-8 xlO" 4 (range 2-8 x 10~5-10x 10"3). After 4 days of therapy, the median
frequency of imipenem-resistant organisms increased to l-5xl0~2 (range
1-3 x 10-3-10-').
A second therapeutic trial, using a higher imipenem dose (120 mg/kg) administered
twice a day, for 7 days essentially confirmed the findings of the first trial. Whereas
before therapy (day 1), the median proportion of highly resistant organisms was
1-3 xlO"4 (range 0-4-41 x 10"4), this value rose to 2-3 xlO"3 (range 10 x 10"4 to
4 0 x 10"2) after therapy. Taken together, both therapeutic trials demonstrated the
persistence of a highly resistant subpopulation of MRS A during high dose therapy of
chronically infected tissue cages.
Discussion
The major objective of this study was to compare the activity of imipenem against
methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains of S. aureus in
an experimental model of chronic tissue cage infections (Lucet et al., 1990), which
represent a significant challenge to antimicrobial therapy (Chuard et al., 1991a).
In-vitro studies have reported high antimicrobial activity (Wise, Andres & Patel, 1981;
Witte et al., 1982) of imipenem against methicillin-susceptible strains of S aureus and
pharmacokinetic studies (Drusano, 1986; Wise et al., 1986) have shown that it is
possible to achieve high levels in humans and animals, suitable for therapy of
Gram-positive bacterial infections. In an experimental model of staphylococcal infec-
tion, namely aortic-valve endocarditis in rats (Baumgartner & Glauser, 1983) and
rabbits (Apellaniz et al., 1991), the activity of imipenem was recorded as at least
equivalent to that of the standard agent, cloxacillin, and even to that of cloxacillin-
gentamicin combination therapy. Our results, which demonstrate significant imipenem
activity against tissue cage infection by MSSA strain 120, agree with those previously
reported for this antibiotic in both animals and humans. Although imipenem is not
considered as a first line agent with which to treat staphylococcal infections, because of
its lack of selectivity, a number of experimental and clinical observations have provided
arguments for its clinical efficacy against MSSA strains.
An interesting and useful feature of imipenem is high resistance to /Mactamases.
High levels of /Mactamase have recently been documented in so-called borderline-
susceptible strains of 5. aureus (Kernodle & Kaiser, 1993), which are devoid of intrinsic
methicillin-resistance. High production of /Mactamase by MSSA strain 120 was
recently observed (Berger-Bachi, B., personal communication), after completion of this
study. It is therefore possible that the high amounts of /Mactamase produced by MSSA
strain 120 decreased, in part, the efficacy of oxacillin against the chronically infecting
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strain. In contrast, the high stability of imipenem to /J-lactamase hydrolysis is likely to
have contributed to the good activity of this agent against MSSA strain 120.
The lack of activity of imipenem against MRSA strain MRGR3 in the rat model of
chronic infection was not anticipated, in view of pilot in-vitro tests performed in
standard conditions and because of the favourable pharmacokinetic properties of this
antimicrobial agent administered at a high dose regimen (120 mg/kg). One significant
factor which contributed to the failure of therapy was the emergence of a highly
resistant subpopulation which grew slowly in the presence of antibiotic. The detection
of such slow-growing imipenem-resistant colonies turned out to be difficult, because it
required a long incubation time for accurate quantification of these organisms.
Surprisingly, the addition of sodium chloride to the growth medium or the use of a
lower temperature of incubation, as usually recommended for the detection of oxacillin
resistance, was not useful in the imipenem context, because neither of these modifica-
tions shortened the time of incubation required for detection of imipenem resistant
organisms.
When the in-vitro and in-vivo data were compared with those in the literature, we
also found that detection of imipenem resistance had been an important part of some
earlier studies (Berry et al., 1986; Chandrasekar et al., 1988). Whereas Chandrasekar
et al. (1988) grew MRSA for 18-24 h at 35°C on mannitol and sodium chloride-
supplemented agar and found good in-vitro and in-vivo activity of imipenem against
these organisms, opposite results and conclusions were obtained by Berry et al. (1986)
who enumerated colonies of methicillin-resistant Stapylococcus epidermidis after 72 h of
growth at 30cC. These major differences in incubation times and temperatures could
afford an explanation for the conflicting results obtained from the studies, in particular
because the former group selected a 24 h growing period which was likely to have been
insufficient to detect the slow-growing, highly resistant subpopulations of MRSA.
In conclusion, imipenem showed good activity in an experimental model of chronic
foreign body-associated infection caused by a methicillin-susceptible strain of
S. aureus. However, the lack of activity of imipenem against the methicillin-resistant
strain of S. aureus in the same model and the observation that an imipenem-resistant
subpopulation grew very slowly and could easily be overlooked in standard culture and
susceptibility testing conditions, are further indications that this antibacterial agent
should not be used for therapy of chronic foreign body infections caused by MRSA.
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